Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NMDA Modulation in Antidepressant Nonresponders With Major Depressive Disorder
NCT05136755Phase 2Recruiting
- Sponsor
- China Medical University Hospital
- Start
- Jan 2022
- Primary completion
- Nov 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial in major depressive disorder (MDD) (2 arms), sponsored by China Medical University Hospital. Primary endpoints: Hamilton Rating Scale for Depression at 8 weeks and Global Assessment of Functioning at 8 weeks. Started Jan 2022; status: recruiting.
02
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on NCT05136755.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05136755.